ContraFect. has filed a patent for lysin-AMP polypeptide constructs and isolated lysin polypeptides, along with pharmaceutical compositions. The patent also covers methods of using these constructs and compositions, as well as isolated polynucleotides encoding them. GlobalData’s report on ContraFect gives a 360-degree view of the company including its patenting strategy. Buy the report here.
Smarter leaders trust GlobalData
According to GlobalData’s company profile on ContraFect, Glycoside hydrolase-based drug compositions was a key innovation area identified from patents. ContraFect's grant share as of January 2024 was 16%. Grant share is based on the ratio of number of grants to total number of patents.
Antibacterial lysin-amp polypeptide constructs and compositions
A recently filed patent (Publication Number: US20240018192A1) discloses a range of isolated polypeptides and polynucleotide sequences encoding lysins, specifically GN217 lysin, GN394 lysin, GN396 lysin, GN408 lysin, GN418 lysin, and GN486 lysin, along with their active fragments or polypeptides with lytic activity. These sequences exhibit at least 80% sequence identity with specific reference sequences. The patent further includes recombinant vectors containing these polynucleotide sequences, isolated host cells, and pharmaceutical compositions comprising lysins and a carrier, formulated for treating Gram-negative bacterial infections. The compositions can be administered alone or in combination with antibiotics to enhance efficacy against bacterial growth, population reduction, or eradication.
Moreover, the patent outlines methods for treating bacterial infections caused by Gram-negative bacteria using the disclosed pharmaceutical compositions. It includes administering the compositions to subjects diagnosed with or at risk of bacterial infections, either topically or systemically. Additionally, a method for augmenting antibiotic efficacy by co-administering antibiotics with isolated lysins is detailed, showing improved inhibition of bacterial growth compared to individual treatments. The patent also covers a method for directly inhibiting the growth, reducing the population, or killing Gram-negative bacteria by contacting them with the isolated lysins, which can target various species like Pseudomonas aeruginosa, Klebsiella spp., and Escherichia coli. Overall, the patent presents a comprehensive approach to utilizing lysins for combating Gram-negative bacterial infections, offering potential advancements in the field of antibacterial therapies.
To know more about GlobalData’s detailed insights on ContraFect, buy the report here.
Premium Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData Patent Analytics tracks bibliographic data, legal events data, point in time patent ownerships, and backward and forward citations from global patenting offices. Textual analysis and official patent classifications are used to group patents into key thematic areas and link them to specific companies
